Category: Biotech

September 7, 2023

Seagen is the biotech sector’s leading developer of antibody-drug conjugates, which deliver cell-killing toxins to diseased cells by attaching them to an antibody that seeks out proteins on tumor cells. Its first, Adcetris, is on track to become a blockbuster […]

August 11, 2023

The success of cancer immunotherapies like Merck & Co.’s Keytruda and Bristol Myers’ Opdivo kicked off a broad search by biopharmaceutical companies for other ways to turn the immune system against cancer. One strategy that drew interest was targeting a […]

July 29, 2023

Investors are much more cautious about the biotechs they back than they were during the sector’s peak a few years ago. Gone are the days when biotechs could easily raise cash and quickly pivot to public markets before starting a […]

July 11, 2023

While much of corporate America rethinks its investment in physical offices, biotechnology companies are still wedded to laboratories and research facilities. Onyx Equities, which earlier this year bought Merck & Co.’s former Kenilworth, New Jersey headquarters, is counting on that […]

July 6, 2023

Initial public offerings in the biotechnology sector have been occuring at a snail’s pace in 2023, prolonging a downturn that’s now lasted nearly two years. Since January, only nine biotech companies have gone public, putting new stock offerings in the […]

June 28, 2023

This afternoon at 2 pm CET (8 am EDT), Bayer AG will host its Pharmaceuticals R&D Event 2023 for Investors. The company will present a deep dive on the innovation strategy in its four therapeutic core areas Oncology, Cardiovascular Diseases, […]

May 12, 2023

Cyclerion formed in April 2019 as a spinoff of Ironwood Pharmaceuticals. Its research revolved around therapies that stimulate sGC, or soluble guanylate cyclase, an enzyme that had already attracted interest from drugmakers as a target for heart and lung diseases. […]

April 14, 2023

Backed by big-name investors, well-known executives and millions of dollars, a freshly launched biotechnology company hopes to turn research from a California lab into new cancer therapies. Named TORL BioTherapeutics, the company is built around discoveries from the lab of […]

April 10, 2023

At least five dozen biotechnology companies have laid off employees so far this year in a sector-wide contraction that has reached large and small drugmakers alike. Brought on by enduring funding challenges, the consolidation has resulted in roughly 3,200 biotech […]

March 24, 2023

The rapid demise of Silicon Valley Bank put an unwelcome spotlight on the financial position of many small biotechnology companies that relied on the storied lender. But to the people who form and build startups, SVB’s collapse is a sidebar […]

March 14, 2023

The panic that accompanied the collapse of the biotechnology sector’s bank of choice ebbed Sunday when the federal government moved to protect all depositors of Silicon Valley Bank. The muscular intervention allayed the fears of the many young biotech companies […]

March 13, 2023

In less than 48 hours, the bank many young biotechnology companies relied on for years was gone. On Friday, the Federal Deposit Insurance Corp. closed Silicon Valley Bank, culminating a stunning collapse that triggered alarms throughout the sector. SVB was […]

February 14, 2023

Kevin Parker is an expert in genomics, immuno-oncology and computational biology. A Ph.D. scientist from Stanford University, he has helped author research in prestigious journals like Science, Nature Medicine and Cell. But two years ago, when Parker was working with […]

January 27, 2023

While global macroeconomic uncertainty continues to impact financing, the pharma industry has focused on UK biotechs to strengthen product pipelines. But with difficult public markets and low investor appetite, new launches were almost unseen in 2022, with public markets contributing […]

January 25, 2023

Goulburn, Dar and Li believe a shift is underway in biotech. The three friends, who have helped build new companies with their respective firms for about a decade, are convinced the search for new drugs is becoming increasingly digitized. Artificial […]

January 10, 2023

Here are five top questions facing emerging biotech companies this year: Will the IPO market open back up? The big question facing investors is whether the biotech industry will see the kind of boom it experienced in 2020 and 2021. […]

January 5, 2023

For biotech to achieve our societal goals, we need to build up the foundational systems that support modern science. Government investment will be critical. Technological resources will also be instrumental — from overcoming current technical skills gaps to modernising how […]

January 4, 2023

The intention is to streamline the process for patients wishing to access their medical records via electronic health record systems (“EHR systems”) and to facilitate the ability for researchers, innovators, and policy makers to use the data in a trusted […]

December 28, 2022

The White House Office of Science and Technology Policy (OSTP) has issued a Request for Information seeking public input on how advances in biotechnology and biomanufacturing can help the U.S. achieve “goals that were previously out of reach and what […]

November 15, 2022

Two months ago, biotechnology startup Good Therapeutics struck it big. A cancer immunotherapy the company was working on drew such interest from Roche that the Swiss pharmaceutical giant paid $250 million, far more than the $30 million the startup had […]